AHA, Other Associations to Senate Finance Committee on Markup of Drug Pricing Bill

The AHA, AAMC and FAH agree with the Committee’s goal of reducing the price of drugs, and applaud many of the steps outlined in the description of the Chairman’s Mark of the Prescription Drug Pricing Reduction Act (PDPRA) of 2019. However, have serious concerns regarding the provisions that reduce reimbursements to providers and hospitals that administer drugs.

Related Resources

Letter/Comment
Public
AHA urges CMS to reconsider its recent guidance to providers requiring them to document Medicare-Medicaid “crossover” bad debt in a manner that is neither…
Action Alert
Member
The AHA has developed comments it will submit to the Centers for Medicare & Medicaid Services (CMS) regarding the agency's proposal to collect negotiated…
Special Bulletin
Public
Download the Special Bulletin: CMS Releases Proposed Rule on Medicaid Drug Value-based Purchasing Arrangements   The Centers for Medicare &…
Special Bulletin
Member
The Centers for Medicare & Medicaid Services (CMS) May 22 released its final rule implementing policy changes for the Medicare Advantage (MA) and Part D…
Letter/Comment
May 26, 2020 The Honorable Chip Roy U.S. House of Representatives 1319 Longworth House Office Building Washington, DC 20515 Dear Representative Roy: On…
Letter/Comment
Public
The AHA urges leaders of the House and Senate Appropriations Subcommittees on Labor, Health and Human Services, Education, and Related Agencies to support…